MK0869 and MK0517 Time-on-Target PET Study.

Trial Profile

MK0869 and MK0517 Time-on-Target PET Study.

Phase of Trial: Phase I

Latest Information Update: 05 Jun 2015

At a glance

  • Drugs Aprepitant (Primary) ; Fosaprepitant (Primary) ; Dexamethasone; Ondansetron
  • Indications Chemotherapy-induced nausea and vomiting; Nausea and vomiting; Postoperative nausea and vomiting
  • Focus Pharmacokinetics
  • Sponsors Merck & Co
  • Most Recent Events

    • 02 Nov 2011 Primary endpoint identified as Neurokinin-1 receptor occupancy as reported by
    • 08 Nov 2010 Status changed from active, no longer recruiting to completed as reported by
    • 08 Nov 2010 Actual end date (Oct 2010) added as reported by
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top